Reference — Pharmacology
Insulin Timing and Administration Protocols
When to give each insulin type, how to time administration relative to meals, and what to monitor throughout. This reference focuses on the protocols and clinical decision points for each insulin class — rapid, short, intermediate, and long-acting — including IV insulin and NPO management. For injection technique, storage, and site rotation, see Insulin Administration.
Educational use only. Insulin type, dose, and timing are individualized and provider-ordered. Blood glucose targets vary by population and clinical situation. Independent double-check is required at most facilities for all insulin doses. Follow institutional protocols. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Timing by Insulin Type — At a Glance
| Type | Examples | Onset | Peak | Duration | Meal Timing |
|---|---|---|---|---|---|
| Rapid-acting | Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra) | 10–15 min | 1–2 hr | 3–5 hr | 0–15 min before meal; confirm meal is in front of patient |
| Short-acting | Regular (Humulin R, Novolin R) | 30–60 min | 2–4 hr | 6–8 hr | 30 min before meal; meal must follow within 30–60 min |
| Intermediate (NPH) | NPH (Humulin N, Novolin N) | 2–4 hr | 4–10 hr | 12–18 hr | Twice daily (AC breakfast/dinner) or bedtime; has a peak — monitor for hypoglycemia |
| Long-acting (basal) | Glargine (Lantus, Basaglar), Detemir (Levemir), Degludec (Tresiba) | 2–4 hr | No significant peak | 20–24+ hr | Once daily at same time each day; not meal-dependent |
Rapid-Acting Insulin — Administration Protocol
Timing: Administer 0–15 minutes before a meal. In the hospital, give only when the meal tray is in front of the patient and they confirm they will eat.
If meal is delayed or refused: Do not administer until the meal arrives. If the patient declines to eat after insulin is given, monitor closely for hypoglycemia and provide a carbohydrate source immediately.
NPO patients: Prandial rapid-acting insulin is withheld for NPO patients. Confirm with provider. Basal insulin may be continued at a reduced dose — provider order required.
Preferred site: Abdomen — fastest, most predictable absorption. Use consistent region for prandial doses.
Short-Acting (Regular) Insulin — Administration Protocol
Timing: Administer 30 minutes before a meal to allow onset before postprandial glucose rise. Requires earlier lead time than rapid-acting insulin.
IV use — only Regular: Regular insulin is the ONLY insulin that can be administered intravenously. All other insulin types are subcutaneous only. Used in DKA protocols, hyperglycemia management, and insulin-dextrose-potassium infusions.
IV protocol requirements: Continuous infusion pump required. Hourly blood glucose checks during infusion. Potassium monitoring every 1–2 hours — insulin drives K⁺ into cells, creating hypokalemia risk. Hold infusion if K⁺ < 3.5 mEq/L until repleted.
Never administer IV Regular insulin without a specific infusion protocol, pump, and continuous monitoring in place.
Intermediate-Acting (NPH) — Administration Protocol
Typical schedule: Twice daily — before breakfast and at bedtime (or before the evening meal). The 4–10 hour peak creates clinically significant hypoglycemia risk: monitor for late-morning and early-morning (Somogyi) hypoglycemia.
Preparation: Gently roll the vial between palms to resuspend. Never shake. Appearance is uniformly cloudy after rolling; discard if it remains clear, clumps, or has particles that do not resuspend.
Mixing with Regular: NPH is the only intermediate-acting insulin that can be mixed with Regular in the same syringe. Draw Regular (clear) first, then NPH (cloudy) — "clear before cloudy." Never draw NPH first, as it may contaminate the Regular vial.
Long-Acting (Basal) Insulin — Administration Protocol
Timing: Once daily at the same time each day. Provides background (basal) insulin coverage over 20–24 hours. Not timed to meals — not a correction insulin.
Consistency is essential: Changing the administration time disrupts 24-hour baseline coverage. If a dose is missed or late, contact the provider before giving a late dose.
Do NOT mix: Glargine, detemir, and degludec must never be mixed with any other insulin. Mixing changes pH and creates an unpredictable combined product.
Appearance alert: Glargine and Regular insulin are both clear solutions. Read the label carefully before every dose — insulin errors frequently involve mix-ups between clear insulins.
Hospitalized patients: Basal insulin may be continued at a reduced dose (typically 50–80% of home dose) during illness or reduced intake. Provider orders required — do not independently adjust the dose.
Meal Coordination
- Confirm meal before prandial insulin: especially rapid-acting. Once given, the patient must eat.
- Patient eating < 50% of meal: notify provider — dose reduction may be ordered.
- NPO for procedures: hold prandial insulin. Basal insulin: follow provider orders (usually continue at reduced dose). Never independently hold or give insulin without an order.
- Continuous tube feeds: interruption of feeds with insulin on board creates significant hypoglycemia risk — have a protocol in place before starting feeds, and monitor closely if feeds are interrupted.
- Carbohydrate counting: in some settings, prandial dose is matched to carbohydrate content of the meal — requires documentation of intake after the meal.
Monitoring Requirements
| Parameter | Timing | Action Threshold |
|---|---|---|
| Blood glucose (subcutaneous insulin) | Before each meal and at bedtime (AC/HS) or per protocol | Hold and notify provider if BG < 70 mg/dL or below facility hold parameter |
| Blood glucose (IV insulin infusion) | Every 1 hour during infusion | Adjust infusion rate per DKA or hyperglycemia protocol |
| Potassium (IV insulin) | Every 1–2 hours during IV insulin infusion | Hold infusion if K⁺ < 3.5 mEq/L; repletion required before resuming |
| Hypoglycemia signs | Ongoing — especially during peak action window for each type | Diaphoresis, tremor, confusion, tachycardia, pallor — confirm with BG check immediately |
Critical Safety Reminders
- Independent double-check before every insulin dose — type, dose, concentration, patient ID, current BG
- Only Regular insulin can be given IV — all others are subcutaneous only
- Long-acting insulins (glargine, detemir, degludec) must never be mixed with any other insulin
- Write "units" in full — never abbreviate as "U" (ISMP Do-Not-Use list — looks like "0", creating 10× overdose risk)
- One insulin pen per patient — never share pens between patients even with a needle change
- U-500 is five times more concentrated than U-100 — requires facility-specific protocol and dedicated U-500 syringes
- Have 15 g fast-acting carbohydrate available at all times for insulin-dependent patients
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with Institute for Safe Medication Practices (ISMP) · FDA prescribing information · The Joint Commission — National Patient Safety Goals. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →